Needham Reiterates Buy on Esperion Therapeutics, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on Esperion Therapeutics (NASDAQ:ESPR) and maintained an $8 price target.
April 10, 2024 | 10:48 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Serge Belanger has reiterated a Buy rating on Esperion Therapeutics and maintained an $8 price target.
The reiteration of a Buy rating and maintenance of an $8 price target by a reputable analyst like Serge Belanger from Needham is a strong positive signal for Esperion Therapeutics. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100